Sana Biotechnology Inc


Sana Biotechnology Inc

  • Price (USD)3.27
  • Today's Change0.16 / 5.14%
  • Shares traded1.16m
  • 1 Year change-60.41%
  • Beta--
Data delayed at least 15 minutes, as of Mar 31 2023 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sana Biotechnology, Inc. is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. The Company focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

  • Revenue in USD (TTM)0.00
  • Net income in USD-269.48m
  • Incorporated2018
  • Employees421.00
  • Location
    Sana Biotechnology Inc188 East Blaine Street, Suite 400SEATTLE 98102United StatesUSA
  • Phone+1 (206) 701-7914
  • Fax+1 (302) 636-5454
  • Websitehttps://sana.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Castle Biosciences Inc137.04m-67.14m603.80m542.00--1.51--4.41-2.58-2.585.2615.030.301210.676.72252,839.50-14.76-8.63-15.82-9.2776.6480.97-48.99-29.807.98--0.0006--45.6558.37-114.55--62.64--
AnaptysBio Inc10.29m-128.72m607.78m96.00--2.37--59.08-4.58-4.580.36539.190.0164--8.96107,156.30-20.54-14.77-21.25-15.44-----1,251.33-226.33----0.00---83.720.5675-122.72--4.30--
Amarin Corporation plc (ADR)369.19m-105.80m609.17m365.00--1.02--1.65-0.2656-0.26560.91991.470.37780.46882.511,011,488.00-10.83-6.67-15.98-9.9570.5876.99-28.66-11.471.77--0.00---36.6915.31-1,468.91--118.60--
ARS Pharmaceuticals Inc1.32m-34.68m614.56m17.00--2.24--466.99-1.25-1.250.0332.900.0043----77,411.77-11.28---11.67-------2,635.41------0.00------61.24------
Phibro Animal Health Corp972.05m36.24m620.52m1.86k17.122.318.860.63840.89480.894824.006.631.072.606.61522,608.104.006.814.918.5530.4631.853.736.131.755.290.639635.8913.074.28-9.58-5.3112.153.71
Sana Biotechnology Inc0.00-269.48m625.75m421.00--1.25-----1.43-1.430.002.610.00----0.00-27.61---30.95--------------0.00------24.29------
Rapt Therapeutics Inc1.53m-83.84m629.17m97.00--2.56--412.03-2.58-2.580.04697.160.0066----15,742.27-36.07-45.24-38.02-48.64-----5,490.37-2,745.89----0.00---59.95---21.15---5.55--
Harrow Health Inc88.60m-14.09m634.12m217.00--22.93--7.16-0.5167-0.51673.230.92290.69294.7216.53408,271.90-11.02-5.92-12.35-7.0271.3569.81-15.90-6.956.000.09010.7927--22.2427.0423.77--27.46--
Arcturus Therapeutics Holdings Inc206.00m9.35m636.53m170.0070.942.3558.533.09-0.0563-0.05637.6010.180.4886--67.201,211,759.002.22-25.203.03-31.59----4.54-118.84--7.940.1833--1,566.7973.78104.59--98.45--
Bicycle Therapeutics PLC (ADR)14.46m-112.72m638.55m236.00--2.35--44.15-3.80-3.800.48769.060.0325--9.5061,283.90-25.32-26.32-28.15-29.28-----779.35-492.29----0.1007--23.6547.67-68.69--76.36--
Mineralys Therapeutics Inc0.00-29.80m639.82m12.00---------0.8042-0.80420.002.87------0.00--------------------0.00-------53.54------
Sinovac Biotech Ltd.9.61bn3.84bn639.90m4.28k----0.09410.066633.6633.6684.2095.150.69372.068.132,243,901.0048.08128.5183.54225.0792.7794.0769.3071.9822.75--0.0013--3,694.36205.828,008.46--124.40--
Hillevax Inc0.00-159.81m648.84m62.00--2.33-----5.08-
Dyne Therapeutics Inc0.00-168.10m649.02m123.00--2.54-----3.24-
Exscientia PLC (ADR)30.28m-123.00m651.71m287.00--1.03--21.52-1.01-1.010.2495.130.05154.936.25105,496.90-20.32---23.43---16.44---406.22--7.55--0.013--182.87---120.94------
Data as of Mar 31 2023. Currency figures normalised to Sana Biotechnology Inc's reporting currency: US Dollar USD

Institutional shareholders

31.88%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 31 Dec 202210.76m5.64%
Canada Pension Plan Investment Boardas of 31 Dec 202210.18m5.34%
The Vanguard Group, Inc.as of 31 Dec 20228.83m4.63%
SSgA Funds Management, Inc.as of 31 Dec 20226.79m3.56%
BlackRock Fund Advisorsas of 31 Dec 20226.61m3.47%
The Public Sector Pension Investment Boardas of 31 Dec 20226.40m3.36%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20224.26m2.24%
Crestline Management LPas of 31 Dec 20223.37m1.77%
Geode Capital Management LLCas of 31 Dec 20221.81m0.95%
Fidelity Management & Research Co. LLCas of 31 Dec 20221.80m0.95%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.